Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes.

Stasi, R; Abruzzese, E; Lanzetta, G; Terzoli, E; Amadori, S

Stasi, R; Abruzzese, E; Lanzetta, G; Terzoli, E; Amadori, S.

Affiliation

Stasi R; Department of Medical Sciences, Regina Apostolorum Hospital, Albano Laziale, Italy. roberto.stasi@uniroma2.it

Ann Oncol ; 16(12): 1921-7, 2005 Dec.

Article in En | MEDLINE | ID: mdl-16166176

Subject(s)

Anemia/drug therapy; Erythropoietin/analogs & derivatives; Myelodysplastic Syndromes/complications; Aged; Aged, 80 and over; Anemia/blood; Anemia/etiology; Apoptosis; Blood Transfusion; Darbepoetin alfa; Erythropoietin/administration & dosage; Erythropoietin/therapeutic use; Female; Follow-Up Studies; Hemoglobins/metabolism; Humans; Injections, Subcutaneous; Male; Middle Aged; Myelodysplastic Syndromes/blood; Quality of Life; Risk Factors; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Myelodysplastic Syndromes / Erythropoietin / Anemia Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2005 Type: Article Affiliation country: Italy

Search on Google

XML

PubMed Links